163 related articles for article (PubMed ID: 22065347)
21. CpG oligodeoxynucleotide augments the antileishmanial activity of miltefosine against experimental visceral leishmaniasis.
Sane SA; Shakya N; Haq W; Gupta S
J Antimicrob Chemother; 2010 Jul; 65(7):1448-54. PubMed ID: 20495208
[TBL] [Abstract][Full Text] [Related]
22. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
23. Comparison between charged aerosol detection and light scattering detection for the analysis of Leishmania membrane phospholipids.
Ramos RG; Libong D; Rakotomanga M; Gaudin K; Loiseau PM; Chaminade P
J Chromatogr A; 2008 Oct; 1209(1-2):88-94. PubMed ID: 18823632
[TBL] [Abstract][Full Text] [Related]
24. Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).
Seifert K; Matu S; Javier Pérez-Victoria F; Castanys S; Gamarro F; Croft SL
Int J Antimicrob Agents; 2003 Oct; 22(4):380-7. PubMed ID: 14522101
[TBL] [Abstract][Full Text] [Related]
25. Miltefosine induces apoptosis in arsenite-resistant Leishmania donovani promastigotes through mitochondrial dysfunction.
Verma NK; Singh G; Dey CS
Exp Parasitol; 2007 May; 116(1):1-13. PubMed ID: 17161839
[TBL] [Abstract][Full Text] [Related]
26. Membrane sterol depletion impairs miltefosine action in wild-type and miltefosine-resistant Leishmania donovani promastigotes.
Saint-Pierre-Chazalet M; Ben Brahim M; Le Moyec L; Bories C; Rakotomanga M; Loiseau PM
J Antimicrob Chemother; 2009 Nov; 64(5):993-1001. PubMed ID: 19749205
[TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs.
Seifert K; Croft SL
Antimicrob Agents Chemother; 2006 Jan; 50(1):73-9. PubMed ID: 16377670
[TBL] [Abstract][Full Text] [Related]
28. HPLC detection of miltefosine using an evaporative light scattering detector.
Lemke A; Kayser O
Pharmazie; 2006 May; 61(5):406-8. PubMed ID: 16724535
[TBL] [Abstract][Full Text] [Related]
29. Unravelling the rate of action of hits in the Leishmania donovani box using standard drugs amphotericin B and miltefosine.
Tegazzini D; Cantizani J; Peña I; Martín J; Coterón JM
PLoS Negl Trop Dis; 2017 May; 11(5):e0005629. PubMed ID: 28542202
[TBL] [Abstract][Full Text] [Related]
30. Novel Agents against Miltefosine-Unresponsive Leishmania donovani.
Das M; Saha G; Saikia AK; Dubey VK
Antimicrob Agents Chemother; 2015 Dec; 59(12):7826-9. PubMed ID: 26392497
[TBL] [Abstract][Full Text] [Related]
31. Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.
Kip AE; Rosing H; Hillebrand MJ; Blesson S; Mengesha B; Diro E; Hailu A; Schellens JH; Beijnen JH; Dorlo TP
Antimicrob Agents Chemother; 2016 Apr; 60(4):2081-9. PubMed ID: 26787691
[TBL] [Abstract][Full Text] [Related]
32. A shotgun tandem mass spectrometric analysis of phospholipids with normal-phase and/or reverse-phase liquid chromatography/electrospray ionization mass spectrometry.
Houjou T; Yamatani K; Imagawa M; Shimizu T; Taguchi R
Rapid Commun Mass Spectrom; 2005; 19(5):654-66. PubMed ID: 15700236
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Leishmania donovani-infected hamsters with miltefosine: analysis of cytokine mRNA expression by real-time PCR, lymphoproliferation, nitrite production and antibody responses.
Gupta R; Kushawaha PK; Samant M; Jaiswal AK; Baharia RK; Dube A
J Antimicrob Chemother; 2012 Feb; 67(2):440-3. PubMed ID: 22121191
[TBL] [Abstract][Full Text] [Related]
34. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes.
Paris C; Loiseau PM; Bories C; Bréard J
Antimicrob Agents Chemother; 2004 Mar; 48(3):852-9. PubMed ID: 14982775
[TBL] [Abstract][Full Text] [Related]
35. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv.
Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S
Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679
[TBL] [Abstract][Full Text] [Related]
36. Enhancement in therapeutic efficacy of miltefosine in combination with synthetic bacterial lipopeptide, Pam3Cys against experimental Visceral Leishmaniasis.
Shakya N; Sane SA; Vishwakarma P; Gupta S
Exp Parasitol; 2012 Jul; 131(3):377-82. PubMed ID: 22626518
[TBL] [Abstract][Full Text] [Related]
37. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms.
Murray HW; Delph-Etienne S
J Infect Dis; 2000 Feb; 181(2):795-9. PubMed ID: 10669380
[TBL] [Abstract][Full Text] [Related]
38. Short report: fluorescent Leishmania: application to anti-leishmanial drug testing.
Singh N; Dube A
Am J Trop Med Hyg; 2004 Oct; 71(4):400-2. PubMed ID: 15516633
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue.
Roseboom IC; Thijssen B; Rosing H; Alves F; Mondal D; Teunissen MBM; Beijnen JH; Dorlo TPC
J Pharm Biomed Anal; 2022 Jan; 207():114402. PubMed ID: 34634528
[TBL] [Abstract][Full Text] [Related]
40. Forced degradation and impurity profiling: recent trends in analytical perspectives.
Jain D; Basniwal PK
J Pharm Biomed Anal; 2013 Dec; 86():11-35. PubMed ID: 23969330
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
